<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta2-gpI) is a <z:chebi fb="0" ids="16247">phospholipid</z:chebi> cofactor with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> properties </plain></SENT>
<SENT sid="1" pm="."><plain>A number of biological functions in the coagulation cascade have been attributed to this cofactor </plain></SENT>
<SENT sid="2" pm="."><plain>Sera from patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) frequently react to beta2-gpI in immunoassays </plain></SENT>
<SENT sid="3" pm="."><plain>Occasionally, patients with thrombotic diathesis present anti-beta2-gpI antibodies in the absence of other <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (<z:chebi fb="21" ids="53713">APA</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>More recently, the presence of beta2-gpI in the atherosclerotic plaque has been proved </plain></SENT>
<SENT sid="5" pm="."><plain>In this article, we initially approach the physiological functions of beta2-gpI in the coagulation cascade, and we also review the importance of anti-beta2gpI antibodies in patients with APS, <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Lastly, we focus the role of anti-beta2-gpI antibodies in coronary and cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>